Expanded access to dibotatug for eligible patients
This trial provides expanded access to the investigational drug dibotatug (DR-01) for patients who are not able to participate in clinical trials but may benefit from this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be eligible for expanded access, which typically means you have a serious or life-threatening condition.
- You must not be able to participate in a clinical trial for this drug.
- You must have a prescription from a doctor for this treatment.
- You must meet the specific requirements set by the drug's expanded access program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program provides access to an investigational drug for people with advanced solid tumors when no other treatment options are available.
This trial provides access to repotrectinib, a targeted therapy for certain cancers, when no other treatment options are available. It aims to give patients a chance to try this medication under a special program.
This program provides access to an investigational drug for people who have already been part of the main clinical trial and have no other treatment options. It aims to give continued treatment when regular access is not possible.
This trial provides early access to a medication called telisotuzumab adizutecan for people who have run out of other treatment choices. It's for those who cannot join a regular clinical trial but might benefit from this experimental drug.
This study tests a new drug called becotatug vedotin, added to standard chemotherapy, for advanced bile duct cancer that has a specific protein called EGFR. The goal is to see if this combination helps shrink tumors or slow the cancer better than standard treatment alone.
This trial tests a new drug combination for advanced bile duct or gallbladder cancer that has not responded to earlier treatments. It aims to see if the combination can shrink tumors and help patients live longer.